FB-825

DB17598InvestigationalProtein Based Therapies

FB-825 is an investigational humanized monoclonal antibody that targets the CεmX domain of the membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells. It is currently being investigated for... It is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin E syndrome (HIES).

Mechanism: Pharmacologically active on Immunoglobulin heavy constant epsilon
Curator reviewed
Also known as: Recombinant humanized immunoglobulin gamma 1 monoclonal antibody (mAb) directed against the CemX segment of human membrane-bound immunoglobulin E (mIgE)
Code names: FB-825

Resolves to

Compound

UNIIYO4XL7781V

Targets

P01854IGHE

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with FB-825, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account